Daiichi Sankyo held Science & Technology Day 2025 on December 16, 2025, where they announced advances in DXd ADC technology and growth strategies for their oncology business.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4568","jir_company_name":"Daiichi Sankyo Company, Limited","jir_importance":"\u26054","jir_publication_date":"2025-12-15","jir_source_link":"https:\/\/www.daiichisankyo.co.jp\/investors\/library\/materials\/","jir_short_summary":"Daiichi Sankyo held Science & Technology Day 2025 on December 16, 2025, where they announced advances in DXd ADC technology and growth strategies for their oncology business.","jir_summary":"### Key Announcements\nAt Science & Technology Day 2025, Daiichi Sankyo announced the latest advancements in DXd ADC technology and growth strategies for its oncology business. Enhertu\u00ae has been used by 194,000 patients worldwide, with global product sales reaching 552.8 billion yen in FY2024, demonstrating a 40% year-over-year growth. Datroway\u00ae achieved global product sales of 10.4 billion yen in Q2 FY2025, marking a 95.9% increase over the previous quarter. Through multiple new indication approvals and clinical trial progress, the company plans to obtain numerous indications for four ADCs by 2030, contributing to approximately six times more patients. On the manufacturing front, a global supply system has been established utilizing both in-house factories and CMOs, aiming for stable supply.\n\n### Impact on Investors\nDaiichi Sankyo\u2019s DXd ADC technology is highly regarded globally, with remarkable sales growth of Enhertu\u00ae and Datroway\u00ae. Future expansion of the oncology business is expected through the acquisition of new indications and successful clinical trials. Strengthening the global supply system and cultivating biopharmaceutical talent prepares the company to meet increasing demand. These initiatives are expected to support sustainable growth and contribute to medium- to long-term value creation for investors.","jir_financial_highlights":"Enhertu\u00ae Global Product Sales: 552.8 billion yen (FY2024) (40% year-over-year growth)\nDatopotamab Deruxtecan (Datroway\u00ae) Global Product Sales: 10.4 billion yen (FY2025 Q2) (95.9% increase quarter-over-quarter)\nEnhertu\u00ae Number of Approved Countries\/Regions: More than 35 (Unknown)","jir_category":"Other,Strategy\/Investment","jir_hashtags":"#DaiichiSankyoCompanyLimited,#IR,#JapaneseStocks","jir_key_figures":"Enhertu\u00ae Global Product Sales 552.8 billion yen (FY2024)\nDatroway\u00ae Global Product Sales 10.4 billion yen (FY2025 Q2)","jir_meta_title":"Daiichi Sankyo Science & Technology Day 2025 and Latest Trends in DXd ADC Technology","jir_meta_description":"Daiichi Sankyo announced advances in DXd ADC technology and growth strategies for the oncology business at Science & Technology Day 2025. Highlights include sales growth of Enhertu\u00ae and Datroway\u00ae and strengthening of the global supply system.","jir_og_title":"Daiichi Sankyo Science & Technology Day 2025 and Latest Trends in DXd ADC Technology","jir_og_description":"Daiichi Sankyo announced the latest advances in DXd ADC technology and growth strategies for the oncology business. Focus is on sales growth of Enhertu\u00ae and Datroway\u00ae and strengthening the global supply system.","jir_og_image_url":"\/assets\/og\/company-ir-general.jpg","jir_chart_data_collection":"[]","ir_related_company":6853,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"general_ir","footnotes":""},"sector":[],"importance":[],"class_list":["post-7227","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n